The da Vinci Single Port Robotic System for Use in Abdominal and Pelvic Surgical Procedures

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Oct 13, 2026 → Sep 21, 2027
See other at-risk trials from City of Hope Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Oct 13, 2026 to Sep 21, 2027
    • Eligibility criteria expanded, about 6 words
  2. Primary and study completion dates: Jan 27, 2026 to Oct 13, 2026v6
  3. Primary and study completion dates: Jan 27, 2025 to Jan 27, 2026v5
  4. Trial status: Suspended to Recruiting
    • Start date changed from estimate of Apr 29, 2024 to Apr 26, 2024
    • Site details revised
    v4
  5. Trial status: Not Yet Recruiting to Suspended Sponsor's reason: funding
    • Primary and study completion dates: Jan 26, 2024 to Jan 27, 2025
    • Start date: Nov 29, 2023 to Apr 29, 2024
    • Site contact updated
    v3
  6. Start date: Jun 29, 2023 to Nov 29, 2023v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This phase II trial test the effectiveness and safety of a single-port robotic device (the da Vinci single port \[SP\]1098) for use in abdominal and pelvic surgeries. The da Vinci SP1098 robotic device can be used to perform less invasive surgeries that allow entry into the body through a single, small incision. The use of this device during surgery may allow surgeons to perform complex procedures that result in less pain, fewer complications and side effects, and improved recovery.
Trial Details
NCT Number NCT05672368
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Disease or Disorder
Related terms Disease
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov